tauopathy


Also found in: Wikipedia.

tauopathy

(tow-ŏp′ŭ-thē) [″ + ″]
Any neurodegenerative disorder in which abnormal levels of tau protein are found in the brain.
References in periodicals archive ?
Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury.
90E-04 ADRA2B,AQP4,CACNB2, 14 disorder CCKBR,CHRNA1,CHRNB4, CHRNG,ESR1,CRIA3,GRIN1, KCNK2,MYOM1,NCAM1,PDE11A Tauopathy 8.
The second model, which demonstrates AD pathology very early on, could be used to examine factors downstream of Abeta-40 and Abeta-42 deposition, such as tauopathy, which are believed to be involved in the neurodegeneration.
Tauopathy occurs when tau builds up in the brain, forming insoluble aggregates inside cells, said Koroshetz.
Using tau, ubiquitin or p62, and TDP-43 immunostains of frontal cortex and hippocampus, the pathologist will in most cases be able to classify the FTLD into either a tauopathy or a non-tau FTLD.
The neuropathological diagnosis in the participants who did not meet pathological criteria for AD included dementia with Lewy bodies, hippocampal sclerosis, Parkinson's disease, subcortical microscopic infarct, mesial temporal lobe neurofibrillary tangles, neurofibrillary tangles with argyrophilic grains and glial tauopathy, and no neuropathology," the authors wrote.
These articles, most of which are fairly recent, address molecular genetic issues, gene expression abnormalities, presenilins, tauopathy, interneuronal beta amyloid neuro-degeneration, lipoprotein receptors in Alzheimer's disease, the role of cholesterol, developments in diagnosis and treatment, in vivo visualization, cathespin B, environmental enrichment, fragile X, category learning (in Parkinson's patients), cerebral disease and dementia and hypertension.
Recent advances, include the discovery of mutations in the tau gene that cause one tauopathy called frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17).
AD is a typical tauopathy, in which NFT formation and amyloid beta peptide deposition are both key pathological features.
The focus of the program is to select compounds using its proprietary Alzheimer's disease (AD) screening assays active against tau oligomers, and to evaluate these compounds in a tauopathy mouse model.
elevated tauopathy and [alpha]-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.